Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma

This is a single arm, open label, multi-center phase 2 study to assess the safety and
anti-tumor activity of intratumoral tavo electroporation in participants with stage IB to
IIIB mycosis fungoides. All participants received up to four cycles of treatment consisting
of three treatment days, Days 1, 5 and 8, in a 12-week cycle. Patients will receive
intra-tumoral injection of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day
distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor
site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
Prior to the first cycle of treatment, the investigator will select at least one lesion, or
affected area in erythrodermic patients, to be left untreated for the duration of the study
to allow for clinical observation of an untreated site. Participants will be followed for
safety and clinical evaluation every 4 weeks. Quality of Life will be assessed using the
Skindex29, Functional Assessment of Cancer Therapy - General (FACT-G) and Visual Analog Scale
for Pruritus (VAS-P) instruments. Survival follow up will occur at 3-month intervals over 2
years following end of study.

Inclusion Criteria

1. Biopsy confirmed mycosis fungoides of stage IB - IIIB;

2. Participants must have failed or have been intolerant to at least one standard of care
therapy;

3. Participants must have a minimum of one lesion, or affected area in erythrodermic
patients (T4/stage III), that meets all following criteria:

- Accessible for pIL-12 electroporation;

- Adequate size such that 6-mm biopsy can be collected prior to treatment;

4. Participants must have one additional lesion, or affected area in erythrodermic
patients, that remains untreated for the duration of the study;

5. Age ≥ 18 years old;

6. Participants must have Eastern Cooperative Oncology Group (ECOG) performance status
0-2;

7. Required wash out period of 4 weeks from last dose for the following prior therapies:

- Topical therapy;

- Radiotherapy (including photo therapy);

- Multi-agent chemotherapy;

- Systemic biological therapy;

- Histone deacetylase inhibitors (HDAC) inhibitors;

- Interferon alpha and other investigational therapies;

8. For women of childbearing potential, negative pregnancy serum test within 14 days to
the first study drug administration, and use of birth control from 30 days prior to
the first day study drug administration and 30 days following last day study drug
administration;

9. Male participants must be surgically sterile, or must agree to use contraception
during the study and at least 30 days following the last day of study drug
administration.

10. Life expectancy of at least 6 months;

11. The patient must have adequate renal and hepatic function as assessed by standard
laboratory criteria within 4 weeks prior to enrollment:

- Creatinine < 2 x upper limit of normal (ULN);

- Serum bilirubin within institutional normal limits;

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN;

- Absolute neutrophil count (ANC) > 1000/mm;

- Platelet count > 100,000 /mm;

12. Able to give informed consent and able to follow guidelines given in the study.

Exclusion Criteria

1. Prior therapy with IL-12 or prior gene therapy;

2. Prior treatment with Campath (alemtuzumab) within 1 year of enrollment;

3. Concurrent immunotherapy, chemotherapy, or radiation therapy for duration of patient
participation on study;

4. Concurrent steroid therapy;

5. Concurrent anticoagulant therapy (acetylsalicylic acid [ASA]≤ 325mg/day allowed);

6. Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess,
etc.) at time of study enrollment;

7. Patients with current evidence of large cell transformation (LCT) with aggressive
disease at study entry (patients with a history of LCT are eligible if pathologic
evidence at study entry indicates there is no presence of LCT);

8. Known history of human immunodeficiency virus (HIV), Human T-cell leukemia virus
(HTLV) -1/2 infection, hepatitis B or hepatitis C (active, prior treatment, or both);

9. No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
Stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease-free for 2 years;

10. Significant cardiovascular disease (i.e. New York Heart Association [NYHA] class 3
congestive heart failure; myocardial infarction within the past 6 months; unstable
angina; coronary angioplasty with the past 6 months; uncontrolled atrial or
ventricular cardiac arrhythmias);

11. Any other medical history, including laboratory results, deemed by the investigator to
be likely to interfere with patient's participation in the study, or to interfere with
the interpretation of the results;

12. Participants with electronic pacemakers or defibrillators are excluded from this study
as the effect of electroporation on these devices is unknown;

13. Pregnant and breast-feeding women are excluded from the study as effects on the fetus
are unknown and there may be a risk of increased fetal wastage.